Clinical Trials Register

Trials with a EudraCT protocol (28,960)
Paediatric studies in scope of Art45 of the Paediatric Regulation (0)

28,960 result(s) found for: Informed Consent. Displaying page 717 of 1,448.

EudraCT Number: 2011-006119-70

Sponsor Protocol Number: 223AS304

Start Date*: 2012-05-15

Sponsor Name:Biogen Idec Research Limited

Full Title: An Open-Label, Multicenter, Extension Study to Evaluate the Long-Term Safety and Efficacy of Dexpramipexole (BIIB050) in Subjects With Amyotrophic Lateral Sclerosis

Medical condition: Amyotrophic Lateral Sclerosis (ALS)

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10029205 - Nervous system disorders	10002026	Amyotrophic lateral sclerosis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: SE (Prematurely Ended) IE (Prematurely Ended) ES (Prematurely Ended) BE (Prematurely Ended) NL (Prematurely Ended) GB (Prematurely Ended) DE (Completed)

Trial results: View results

EudraCT Number: 2011-000520-15

Sponsor Protocol Number: B1821010

Start Date*: 2011-09-29

Sponsor Name:Pfizer Inc., 235 East 42nd Street, New York, NY 10017

Full Title: A MULTICENTER, OPEN LABEL STUDY TO COMPARE ON DEMAND TREATMENT TO A PROPHYLAXIS REGIMEN OF NONACOG ALFA (BENEFIX) IN SUBJECTS WITH MODERATELY SEVERE TO SEVERE HEMOPHILIA B (FIX:C ≤2%)

Medical condition: Hemophilia B

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	15.0	10010331 - Congenital, familial and genetic disorders	10060614	Hemophilia B (Factor IX)	LLT

Population Age: Adolescents, Under 18, Adults, Elderly

Gender: Male

Trial protocol: PL (Completed) BG (Completed) GR (Completed) Outside EU/EEA

Trial results: View results

EudraCT Number: 2020-001592-33

Sponsor Protocol Number: 0204

Start Date*: 2020-11-17

Sponsor Name:Rigshospitalet

Full Title: Maternal Mental Health (MAMA) Study. Short time estrogen as a candidate strategy to prevent postpartum depression in a high-risk group

Medical condition: Perinatal depression with postpartum onset

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	20.0	100000004873	10056393	Postpartum depression	LLT

Population Age: Newborns, Under 18, Adults

Gender: Male, Female

Trial protocol: DK (Trial now transitioned)

Trial results: (No results available)

EudraCT Number: 2019-002786-35

Sponsor Protocol Number: CUA1

Start Date*: 2020-06-25

Sponsor Name:Charlotte Uggerhøj Andersen

Full Title: Pharmacokinetics and side effects for tetrahydrocannabinol and cannabidiol (Sativex) among patients with chronic kidney disease and patients on dialysis.

Medical condition: Chronic kidney disease

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	23.1	10038359 - Renal and urinary disorders	10064848	Chronic kidney disease	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DK (Completed)

Trial results: View results

EudraCT Number: 2008-006831-10

Sponsor Protocol Number: 1199.15

Start Date*: Information not available in EudraCT

Sponsor Name:Boehringer Ingelheim Pharma GmbH & Co. KG

Full Title: Multicenter, randomised, double-blind Phase III trial to investigate the efficacy and safety of BIBF 1120 in combination with carboplatin and paclitaxel compared to placebo plus carboplatin and pac...

Medical condition: Advanced ovarian cancer, fallopian tube cancer or primary peritoneal cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
	19.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10026469	Malignant neoplasm of specified parts of peritoneum	LLT
	19.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10026340	Malignant neoplasm of peritoneum, unspecified	LLT
	19.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10016180	Fallopian tube cancer	PT
	19.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10033128	Ovarian cancer	PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: DE (Completed) FR (Completed) SE (Completed) BE (Completed) PT (Completed) SK (Completed) DK (Completed) AT (Completed) NL (Completed) FI (Completed) PL (Completed) IT (Completed) GR (Completed) CZ (Completed) ES (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2006-000471-14	Sponsor Protocol Number: TRA105325	Start Date*: 2006-06-13
Sponsor Name:GlaxoSmithKline Research and Development Limited
Full Title: EXTEND (Eltrombopag eXTENded Dosing Study): An extension study of eltrombopag olamine (SB-497115-GR) in adults, with idiopathic thrombocytopenic purpura (ITP), previously enrolled in an eltrombopa...
Medical condition: Immune thrombocytopenic purpura (ITP)
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: SI (Completed) SE (Completed) DE (Completed) ES (Completed) IE (Completed) NL (Completed) GR (Completed) FR (Completed) SK (Completed) GB (Completed) CZ (Completed) DK (Completed) IT (Completed) FI (Completed) AT (Completed)
Trial results: View results

EudraCT Number: 2014-000565-47

Sponsor Protocol Number: BAY59-7939/14372

Start Date*: 2014-07-25

Sponsor Name:Bayer HealthCare AG

Full Title: Multicenter, open-label, active-controlled, randomized study to evaluate the efficacy and safety of an age-and body weight-adjusted rivaroxaban regimen compared to standard of care in children with...

Medical condition: Venous Thrombosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.0	100000004866	10066899	Venous thromboembolism	LLT

Population Age: Infants and toddlers, Children, Adolescents, Under 18

Gender: Male, Female

Trial protocol: ES (Completed) AT (Completed) IT (Completed) NL (Completed) BE (Completed) DE (Completed) GB (Completed) PL (Completed) IE (Completed) FR (Completed) FI (Completed) HU (Completed) SE (Completed) SK (Completed) PT (Completed)

Trial results: View results

EudraCT Number: 2009-013256-69

Sponsor Protocol Number: CQVA149A2304

Start Date*: 2010-04-13

Sponsor Name:Novartis Pharma Services AG

Full Title: A 64-week treatment, multi-center, randomized, double-blind, parallel-group, active controlled study to evaluate the effect of QVA149 (110/50 μg o.d.) vs NVA237 (50 μg o.d.) and open-label tiotropi...

Medical condition: Chronic Obstructive Pulmonary Disease (COPD)

Disease:	Version	SOC Term	Classification Code	Term	Level
	12.1		10010952	COPD	LLT
	12.1		10010953	COPD exacerbation	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) HU (Completed) FI (Completed) CZ (Completed) NL (Completed) SK (Completed) ES (Completed) GB (Completed) DK (Completed) FR (Completed) EE (Completed) IE (Completed) IT (Completed) PL (Completed) AT (Completed) GR (Completed)

Trial results: View results

EudraCT Number: 2005-004094-25

Sponsor Protocol Number: EGD-EC-003

Start Date*: 2006-01-05

Sponsor Name:Astellas Pharma Europe B.V.

Full Title: A phase IIIb randomized study of intermittent versus continuous androgen deprivation therapy using ELIGARD 22.5 mg 3-month depot in subjects with relapsing or locally advanced prostate cancer who a...

Medical condition: Histologically or cytologically confirmed adenocarcinoma of the prostate (PCa) meeting the following criteria: - Locally adv. (stage T3 or T4) PCa, N0 or N+, M0 with PSA >= 5 ng/ml, or - Relapsing ...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8.0		10060862		LLT

Population Age: Adults, Elderly

Gender: Male

Trial protocol: CZ (Completed) AT (Prematurely Ended) FI (Completed) SK (Completed) IE (Completed) HU (Completed) DE (Completed) ES (Completed) SE (Completed) GB (Completed) PT (Completed) BE (Completed) DK (Completed) GR (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2008-000498-40

Sponsor Protocol Number: CRAD001N2301

Start Date*: 2009-06-08

Sponsor Name:Novartis Pharma Services AG

Full Title: A randomized, double-blind, placebo-controlled, multicenter phase III study of RAD001 adjuvant therapy in poor risk patients with Diffuse Large B-Cell Lymphoma (DLBCL) of RAD001 versus matching pla...

Medical condition: Diffuse Large B-Cell Lymphoma

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	17.1	10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)	10012818	Diffuse large B-cell lymphoma	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: CZ (Completed) HU (Completed) SK (Completed) AT (Completed) IT (Completed) DE (Completed) GR (Completed) ES (Completed)

Trial results: View results

EudraCT Number: 2007-007942-36

Sponsor Protocol Number: EFC6520

Start Date*: 2008-09-30

Sponsor Name:sanofi-aventis recherche & développement

Full Title: A Multinational, Multicenter, Randomized, Double Blind Study comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Prevention of Venous Thromboembolism in Patients Undergoing Major A...

Medical condition: The subjects who will participate to this clinical trial are patients undergoing major abdominal surgery.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10049909	Venous thromboembolism prophylaxis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) ES (Completed) LV (Completed) EE (Completed) DK (Completed) BE (Completed) SE (Completed) HU (Completed) CZ (Completed) LT (Completed) SI (Completed) IT (Completed) SK (Completed) BG (Completed) AT (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2016-000814-31

Sponsor Protocol Number: CAIN457F3302

Start Date*: 2016-08-03

Sponsor Name:Novartis Farmacéutica, S.A.

Full Title: MAXIMISE (Managing AXIal Manifestations in Psoriatic Arthritis with SEcukinumab), a randomized, double-blind, placebo-controlled, multicenter, 52 week study to assess the efficacy and safety of sec...

Medical condition: Axial Psoriatic Arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	19.0	100000004859	10037160	Psoriatic arthritis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: ES (Completed) CZ (Completed) FR (Completed) GB (Completed) HU (Completed) EE (Completed) IE (Completed) BE (Completed) FI (Completed) DK (Prematurely Ended) DE (Completed) BG (Completed) GR (Completed) PL (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2009-011137-26

Sponsor Protocol Number: P06129

Start Date*: 2009-10-05

Sponsor Name:Schering-Plough Research Institute, A Division of Schering Corporation

Full Title: An open-label study assessing the addition of subcutaneous golimumab (GLM) to conventional disease-modifying antirheumatic drug (DMARD) therapy in biologic-naïve subjects with rheumatoid arthritis ...

Medical condition: Active Rheumatoid Arthritis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.0	10028395 - Musculoskeletal and connective tissue disorders	10039073	Rheumatoid arthritis	PT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: DE (Completed) ES (Completed) FI (Completed) NL (Completed) HU (Completed) AT (Completed) FR (Completed) IE (Completed) IT (Completed) CZ (Completed) BE (Completed) GR (Completed) DK (Completed) SK (Completed) PT (Completed) PL (Completed) GB (Completed)

Trial results: View results

EudraCT Number: 2011-000410-18	Sponsor Protocol Number: 061002	Start Date*: 2011-05-05
Sponsor Name:Baxter Innovations GmbH
Full Title: A PHASE 3b CLINICAL STUDY TO ASSESS WHETHER REGULAR ADMINISTRATION OF ADVATE IN THE ABSENCE OF IMMUNOLOGICAL DANGER SIGNALS REDUCES THE INCIDENCE RATE OF INHIBITORS IN PREVIOUSLY UNTREATED PATIENTS...
Medical condition: Prevention of inhibitor formation, and immune tolerance induction in patients with severe and moderately severe hemophilia A by early and low-dose prophylactic ADVATE therapy
Disease:
Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18		Gender: Male
Trial protocol: AT (Prematurely Ended) DE (Completed) SK (Prematurely Ended) LT (Prematurely Ended) GB (Prematurely Ended) HU (Prematurely Ended) CZ (Prematurely Ended) SE (Prematurely Ended) BE (Prematurely Ended) BG (Completed) ES (Prematurely Ended) NL (Prematurely Ended) GR (Prematurely Ended) PL (Prematurely Ended) PT (Completed)
Trial results: View results

EudraCT Number: 2005-003862-40

Sponsor Protocol Number: BO17708

Start Date*: 2006-01-20

Sponsor Name:F. Hoffmann-La Roche Limited

Full Title: Estudio multicéntrico, randomizado, doble ciego, controlado con placebo, para evaluar la eficacia y seguridad de bevacizumab en combinación con docetaxel, en comparación con docetaxel más placebo, ...

Medical condition: Cáncer de mama metastásico Metastatic breast cancer

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	8		10055113		PT

Population Age: Adults, Elderly

Gender: Female

Trial protocol: ES (Completed) BE (Completed) AT (Completed) GB (Completed) SE (Completed) PT (Completed) DE (Completed) LT (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2008-000228-13

Sponsor Protocol Number: EFC10572

Start Date*: 2008-08-22

Sponsor Name:sanofi-aventis recherche & développement

Full Title: A Multinational, Multicenter, Randomized, Double-Blind Study Comparing the Efficacy and Safety of AVE5026 with enoxaparin for the Primary Prevention of Venous Thromboembolism in Acutely Ill Medical...

Medical condition: The subjects who will partcipate to this clinical trial are acutely ill medical patients with restricted mobility.

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10049909	Venous thromboembolism prophylaxis	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: AT (Completed) LV (Prematurely Ended) FR (Completed) CZ (Completed) NL (Completed) HU (Completed) ES (Completed) PT (Completed) EE (Completed) BE (Completed) LT (Prematurely Ended) IT (Prematurely Ended) PL (Completed) SI (Completed) DE (Prematurely Ended) GB (Prematurely Ended)

Trial results: View results

EudraCT Number: 2007-004817-33	Sponsor Protocol Number: EFC10295	Start Date*: 2008-02-19
Sponsor Name:sanofi-aventis recherche&développement
Full Title: A multicenter, randomized, double-blind, assessor-blind, non-inferiority study comparing the efficacy and safety of once-weekly subcutaneous biotinylated idraparinux (SSR126517E) with oral adjuste...
Medical condition: The subjects who will participate to this clinical trial are not healthy volonteers. They have Permanent, persistent or paroxysmal non-valvular atrial fibrillation that is ECG-documented, with an i...
Disease:
Population Age: Adults, Elderly		Gender: Male, Female
Trial protocol: SE (Prematurely Ended) GB (Prematurely Ended) NL (Completed) ES (Completed) FI (Completed) EE (Completed) GR (Prematurely Ended) DK (Prematurely Ended) AT (Prematurely Ended) CZ (Prematurely Ended) SK (Completed) PT (Completed) BG (Completed) IT (Prematurely Ended) LT (Completed)
Trial results: View results

EudraCT Number: 2009-013652-69

Sponsor Protocol Number: AI447-016

Start Date*: 2010-01-19

Sponsor Name:Bristol-Myers Squibb International Corporation

Full Title: A Phase 2a/2b study of BMS-650032 in Combination With Peginterferon Alfa-2a (Pegasys) and Ribavirin (Copegus) in Treatment-Naive Subjects with Genotypes 1 and 4 Chronic Hepatitis C Infection.

Medical condition: Chronic Hepatitis C Virus Infection (Genotypes 1 and 4) in Treatment-Naive Subjects

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10008912	Chronic hepatitis C	LLT

Population Age: Adults, Elderly

Gender: Male, Female

Trial protocol: FR (Completed) GB (Completed) DE (Completed) ES (Completed) IE (Completed) IT (Completed)

Trial results: View results

EudraCT Number: 2009-010551-26

Sponsor Protocol Number: D0102C00003

Start Date*: 2009-08-10

Sponsor Name:AstraZeneca AB

Full Title: A Phase I/II Multi-centre Study of AZD8931 in Combination with Weekly Paclitaxel to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy in Patients with Advanced Solid Tumours and in a S...

Medical condition: Phase I part of the study: Solid tumours that are refractory to standard therapies Phase II part of the study: trastuzumab- or lapatinib-ineligible patients with locally advanced (not amenable to s...

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	9.1		10049280	Solid tumour	LLT

Population Age: Adults

Gender: Male, Female

Trial protocol: GB (Completed) CZ (Completed) HU (Completed) SE (Completed) FR (Completed) IT (Completed) BG (Completed) BE (Completed)

Trial results: View results

EudraCT Number: 2007-002693-66

Sponsor Protocol Number: 0822-018

Start Date*: 2007-11-13

Sponsor Name:MERCK SHARP & DOHME CORP.

Full Title: A Phase III Randomized, Placebo-Controlled Clinical Trial to Assess the Safety and Efficacy of MK-0822 to Reduce the Risk of Fracture in Osteoporotic Postmenopausal Women Treated With Vitamin D an...

Medical condition: Postmenopausal Osteoporosis

Disease:	Version	SOC Term	Classification Code	Term	Level
Disease:	14.1	10028395 - Musculoskeletal and connective tissue disorders	10031285	Osteoporosis postmenopausal	PT

Population Age: Elderly

Gender: Female

Trial protocol: LT (Completed) DK (Completed) CZ (Prematurely Ended) PL (Prematurely Ended) GB (Prematurely Ended) DE (Completed) FR (Prematurely Ended) BE (Prematurely Ended) LV (Completed) EE (Completed) IT (Completed) ES (Completed) BG (Prematurely Ended)

Trial results: View results

Subscribe to this Search
To subscribe to the RSS feed for this search click here

. This will provide an RSS feed for clinical trials matching your search that have been added or updated in the last 7 days.

Download Options:
Number of Trials to download:

Download Content:

Download Format:


Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.

Query did not match any studies.

Select Country:	Select Age Range:
Select Trial Status:	Select Trial Phase:
Select Gender:
Select Date Range: to
Select Rare Disease:
IMP with orphan designation in the indication
Orphan Designation Number:
Results Status:
Clear advanced search filters

Austria
Belgium
Bulgaria
Croatia
Cyprus
Czechia
Denmark
Estonia
Finland
France
Germany
Greece
Hungary
Iceland
Ireland
Italy
Latvia
Liechtenstein
Lithuania
Luxembourg
Malta
Netherlands
Norway
Poland
Portugal
Romania
Slovakia
Slovenia
Spain
Sweden
United Kingdom
Outside EU/EEA

Clinical trials for Informed Consent